Literature DB >> 22836161

Separation of advanced from mild hepatic fibrosis by quantification of the hepatobiliary uptake of Gd-EOB-DTPA.

Bengt Norén1, Mikael Fredrik Forsgren, Olof Dahlqvist Leinhard, Nils Dahlström, Johan Kihlberg, Thobias Romu, Stergios Kechagias, Sven Almer, Örjan Smedby, Peter Lundberg.   

Abstract

OBJECTIVES: To apply dynamic contrast-enhanced (DCE) MRI on patients presenting with elevated liver enzymes without clinical signs of hepatic decompensation in order to quantitatively compare the hepatocyte-specific uptake of Gd-EOB-DTPA with histopathological fibrosis stage.
METHODS: A total of 38 patients were prospectively examined using 1.5-T MRI. Data were acquired from regions of interest in the liver and spleen by using time series of single-breath-hold symmetrically sampled two-point Dixon 3D images (non-enhanced, arterial and venous portal phase; 3, 10, 20 and 30 min) following a bolus injection of Gd-EOB-DTPA (0.025 mmol/kg). The signal intensity (SI) values were reconstructed using a phase-sensitive technique and normalised using multiscale adaptive normalising averaging (MANA). Liver-to-spleen contrast ratios (LSC_N) and the contrast uptake rate (K (Hep)) were calculated. Liver biopsy was performed and classified according to the Batts and Ludwig system.
RESULTS: Area under the receiver-operating characteristic curve (AUROC) values of 0.71, 0.80 and 0.78, respectively, were found for K (Hep), LSC_N10 and LSC_N20 with regard to severe versus mild fibrosis. Significant group differences were found for K (Hep) (borderline), LSC_N10 and LSC_N20.
CONCLUSIONS: Liver fibrosis stage strongly influences the hepatocyte-specific uptake of Gd-EOB-DTPA. Potentially the normalisation technique and K (Hep) will reduce patient and system bias, yielding a robust approach to non-invasive liver function determination.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22836161     DOI: 10.1007/s00330-012-2583-2

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  27 in total

1.  Sources of variability in histological scoring of chronic viral hepatitis.

Authors:  Marie-Christine Rousselet; Sophie Michalak; Florence Dupré; Anne Croué; Pierre Bedossa; Jean-Paul Saint-André; Paul Calès
Journal:  Hepatology       Date:  2005-02       Impact factor: 17.425

2.  Magnetic resonance elastography for the noninvasive staging of liver fibrosis.

Authors:  Laurent Huwart; Christine Sempoux; Eric Vicaut; Najat Salameh; Laurence Annet; Etienne Danse; Frank Peeters; Leon C ter Beek; Jacques Rahier; Ralph Sinkus; Yves Horsmans; Bernard E Van Beers
Journal:  Gastroenterology       Date:  2008-04-04       Impact factor: 22.682

3.  Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot study.

Authors:  O Dahlqvist Leinhard; N Dahlström; J Kihlberg; P Sandström; T B Brismar; O Smedby; P Lundberg
Journal:  Eur Radiol       Date:  2011-10-09       Impact factor: 5.315

4.  Dynamic contrast-enhanced magnetic resonance imaging with Gd-EOB-DTPA for the evaluation of liver fibrosis in chronic hepatitis patients.

Authors:  Bang-Bin Chen; Chao-Yu Hsu; Chih-Wei Yu; Shwu-Yuan Wei; Jia-Horng Kao; Hsuan-Shu Lee; Tiffany Ting-Fang Shih
Journal:  Eur Radiol       Date:  2011-08-31       Impact factor: 5.315

Review 5.  Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance.

Authors:  J König; A T Nies; Y Cui; I Leier; D Keppler
Journal:  Biochim Biophys Acta       Date:  1999-12-06

6.  Quantitative evaluation of liver function with use of gadoxetate disodium-enhanced MR imaging.

Authors:  Akira Yamada; Takeshi Hara; Feng Li; Yasunari Fujinaga; Kazuhiko Ueda; Masumi Kadoya; Kunio Doi
Journal:  Radiology       Date:  2011-06-28       Impact factor: 11.105

7.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

8.  Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging--preliminary observations.

Authors:  Haruo Watanabe; Masayuki Kanematsu; Satoshi Goshima; Hiroshi Kondo; Minoru Onozuka; Noriyuki Moriyama; Kyongtae T Bae
Journal:  Radiology       Date:  2011-01-19       Impact factor: 11.105

9.  Quantitative evaluation of liver function with MRI Using Gd-EOB-DTPA.

Authors:  Hun-Kyu Ryeom; Seong-Hun Kim; Jong-Yeol Kim; Hye-Jeong Kim; Jong-Min Lee; Yong-Min Chang; Yong-Sun Kim; Duk-Sik Kang
Journal:  Korean J Radiol       Date:  2004 Oct-Dec       Impact factor: 3.500

10.  Absolute quantification of human liver metabolite concentrations by localized in vivo 31P NMR spectroscopy in diffuse liver disease.

Authors:  Bengt Norén; Peter Lundberg; Marcus Ressner; Staffan Wirell; Sven Almer; Orjan Smedby
Journal:  Eur Radiol       Date:  2004-09-03       Impact factor: 5.315

View more
  26 in total

1.  Can functional parameters from hepatobiliary phase of gadoxetate MRI predict clinical outcomes in patients with cirrhosis?

Authors:  Kumar Sandrasegaran; Enming Cui; Reem Elkady; Pauley Gasparis; Gitasree Borthakur; Mark Tann; Suthat Liangpunsakul
Journal:  Eur Radiol       Date:  2018-04-12       Impact factor: 5.315

2.  Increase in left liver lobe function after preoperative right portal vein embolisation assessed with gadolinium-EOB-DTPA MRI.

Authors:  Dominik Geisel; Lutz Lüdemann; Thomas Keuchel; Maciej Malinowski; Daniel Seehofer; Martin Stockmann; Bernd Hamm; Bernhard Gebauer; Timm Denecke
Journal:  Eur Radiol       Date:  2013-05-08       Impact factor: 5.315

3.  Diagnostic value of Gd-EOB-DTPA-enhanced MR cholangiography in non-invasive detection of postoperative bile leakage.

Authors:  Melahat Kul; Ayşe Erden; Ebru Düşünceli Atman
Journal:  Br J Radiol       Date:  2017-02-09       Impact factor: 3.039

4.  A New Model for MR Evaluation of Liver Function with Gadoxetic Acid, Including Both Uptake and Excretion.

Authors:  Daniel Truhn; Christiane K Kuhl; Alexander Ciritsis; Alexandra Barabasch; Nils A Kraemer
Journal:  Eur Radiol       Date:  2018-06-15       Impact factor: 5.315

Review 5.  Evaluation of hepatic fibrosis: a review from the society of abdominal radiology disease focus panel.

Authors:  Jeanne M Horowitz; Sudhakar K Venkatesh; Richard L Ehman; Kartik Jhaveri; Patrick Kamath; Michael A Ohliger; Anthony E Samir; Alvin C Silva; Bachir Taouli; Michael S Torbenson; Michael L Wells; Benjamin Yeh; Frank H Miller
Journal:  Abdom Radiol (NY)       Date:  2017-08

6.  Efficacy of liver parenchymal enhancement and liver volume to standard liver volume ratio on Gd-EOB-DTPA-enhanced MRI for estimation of liver function.

Authors:  Tomohide Yoneyama; Yoshihiko Fukukura; Kiyohisa Kamimura; Koji Takumi; Aya Umanodan; Shinichi Ueno; Masayuki Nakajo
Journal:  Eur Radiol       Date:  2013-12-20       Impact factor: 5.315

7.  Vascular input function correction of inflow enhancement for improved pharmacokinetic modeling of liver DCE-MRI.

Authors:  Jia Ning; Tilman Schubert; Kevin M Johnson; Alejandro Roldán-Alzate; Huijun Chen; Chun Yuan; Scott B Reeder
Journal:  Magn Reson Med       Date:  2017-11-10       Impact factor: 4.668

Review 8.  CT and MR perfusion techniques to assess diffuse liver disease.

Authors:  Maxime Ronot; Benjamin Leporq; Bernard E Van Beers; Valérie Vilgrain
Journal:  Abdom Radiol (NY)       Date:  2020-11

9.  Dynamic Contrast-Enhanced MRI of OATP Dysfunction in Diabetes.

Authors:  Dorela D Shuboni-Mulligan; Maciej Parys; Barbara Blanco-Fernandez; Christiane L Mallett; Regina Schnegelberger; Marilia Takada; Shatadru Chakravarty; Bruno Hagenbuch; Erik M Shapiro
Journal:  Diabetes       Date:  2018-11-28       Impact factor: 9.461

Review 10.  Noninvasive diagnosis of cirrhosis: a review of different imaging modalities.

Authors:  Riccardo De Robertis; Mirko D'Onofrio; Emanuele Demozzi; Stefano Crosara; Stefano Canestrini; Roberto Pozzi Mucelli
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.